5:17PM Sagent Pharma annoucnes amendment to supply agreement with Actavis (ACT) (SGNT) 17.01 +0.95 : Co announced the signing of an amendment to its Manufacturing and Supply Agreement with Actavis. The amended agreement provides for an enhanced profit split in favor of Sagent, a revised line-up of products including the addition of a zoledronic acid injection, 4 mg vial product, a modified termination date of December 31, 2014 and a one-time termination fee of $5 million payable to Sagent.
3:55PM Sagent Pharma announces approval and launch of Zoledronic Acid Injection 4mg (SGNT) 16.84 +0.78 : Co announced the approval and launch of Zoledronic Acid Injection 4 mg, the generic form of the bisphosphonate Zometa, in a latex-free plastic vial. According to IMS data for the 12 months ending January 2013, the U.S. market for Zoledronic Acid Injection 4 mg approximated $606 million. As with all products in Sagent's portfolio, Zoledronic Acid Injection features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
News 
Market Data 
Discover 
